J Korean Med Sci.  2011 Jun;26(6):753-758. 10.3346/jkms.2011.26.6.753.

Relationship between Chronic Kidney Disease and Risk of Coronary Heart Disease in Korean Men

• Ryoo JH
• Kim SG
• Suh BS
• Kim DI
• Park SK

• KMID: 1785960
• DOI: http://doi.org/10.3346/jkms.2011.26.6.753

Abstract

There have been many epidemiological researches of chronic kidney disease (CKD), accompanied by an increase in the incidence of coronary heart disease (CHD). However, as far as we know, little research has been done to examine the extent of the relationship between CKD and CHD as estimated by Framingham risk score (FRS) in Korean men. CKD was defined as either proteinuria or an eGFR of < 60 mL/min per 1.73 m2. The FRS has been used to predict the 10-yr risk of coronary events and usually divided into three levels of risk < 10% (low), 10%-19% (intermediate) and > or = 20% (high). We defined FRS > or = 10% as more-than-a-moderate CHD risk group and FRS > or = 20% as a high CHD risk group, respectively. After adjusting for covariates, multivariable-adjusted logistic regression analyses showed a strong statistical significant relationship between CKD and high risk of CHD (adjusted OR, 1.95 [95% CI, 1.32-2.87]). Dipstick urinalysis and eGFR can be readily measured in most clinical settings. The measurement of kidney function may represent a relatively inexpensive and efficient way to identify individuals at higher risk for CHD.

Keyword

Renal Failure, Chronic Kidney Disease; Coronary Heart Disease; Framingham Risk Score

MeSH Terms

Adult
Aged
Coronary Disease/epidemiology/*etiology
Glomerular Filtration Rate
Humans
Kidney Failure, Chronic/*complications
Logistic Models
Male
Middle Aged
Odds Ratio
Proteinuria/complications
Renal Insufficiency, Chronic/*complications
Republic of Korea
Risk Factors

Reference

1. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004. 351:1296–1305.

2. Kiberd B. The chronic kidney disease epidemic: stepping back and looking forward. J Am Soc Nephrol. 2006. 17:2967–2973.

3. Weiner DE, Tighiouart H, Amin MG, Stark PC, MacLeod B, Griffith JL, Salem DN, Levey AS, Sarnak MJ. Chronic kidney disease as a risk factor for cardiovascular disease and all-cause mortality: a pooled analysis of community-based studies. J Am Soc Nephrol. 2004. 15:1307–1315.

4. Hsu CY, Chertow GM. Chronic renal confusion: insufficiency, failure, dysfunction, or disease. Am J Kidney Dis. 2000. 36:415–418.

5. Iseki K, Ikemiya Y, Fukiyama K. Risk factors of end-stage renal disease and serum creatinine in a community based mass screening. Kidney Int. 1997. 51:850–854.

6. US Renal Data System. USRDS 2003 Annual Data Report. The National Institutes of Health, National Institutes of Diabetes and Digestive and Kidney Diseases. 2003. Bethesda, MD: United States Renal Data System.

7. Stengel B, Billon S, Van Dijk PC, Jager KJ, Dekker FW, Simpson K, Briggs JD. Trends in the incidence of renal replacement therapy for end-stage renal disease in Europe, 1990-1999. Nephrol Dial Transplant. 2003. 18:1824–1833.

8. National Kidney Foundation. K/DOQI Clinical Practice Guidelines for Chronic Kidney Disease: Evaluation, classification, and stratification. Am J Kidney Dis. 2002. 39:2 Suppl 1. S1–S266.

9. Xue JL, Ma JZ, Louis TA, Collins AJ. Forecast of the number of patients with end-stage renal disease in the United States to the year 2010. J Am Soc Nephrol. 2001. 12:2753–2758.

10. Korean Society of Nephrology, Registry Committee. Renal replacement therapy in Korea: Insan Memorial Dialysis Registry. 2009.

11. Centers for Disease Control and Prevention (CDC). Prevalence of chronic kidney disease and associated risk factors-United States, 1999-2004. MMWR Morb Mortal Wkly Rep. 2007. 56:161–165.

12. National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report. Circulation. 2002. 106:3143–3421.

13. Culleton BF, Larson MG, Wilson PW, Evans JC, Parfrey PS, Levy D. Cardiovascular disease and mortality in a community-based cohort with mild renal insufficiency. Kidney Int. 1999. 56:2214–2219.

14. Garg AX, Clark WF, Haynes RB, House AA. Moderate renal insufficiency and the risk of cardiovascular mortality: results from the NHANES I. Kidney Int. 2002. 61:1486–1494.

15. Wannamethee SG, Shaper AG, Perry IJ. Serum creatinine concentration and risk of cardiovascular disease: a possible marker for increased risk of stroke. Stroke. 1997. 28:557–563.

16. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. Modification of Diet in Renal Disease Study Group. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Ann Intern Med. 1999. 130:461–470.

17. Levey AS, Coresh J, Balk E, Kausz AT, Levin A, Steffes MW, Hogg RJ, Perrone RD, Lau J, Eknoyan G. National Kidney Foundation. National Kidney Foundation practice guidelines for chronic kidney disease: Evaluation, classification, and stratification. Ann Intern Med. 2003. 139:137–147.

18. Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr, Clark LT, Hunninghake DB, Pasternak RC, Smith SC Jr, Stone NJ. National Heart, Lung, and Blood Institute. American College of Cardiology Foundation. American Heart Association. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004. 110:227–239.

19. Whaley-Connell A, Pavey BS, Chaudhary K, Saab G, Sowers JR. Renin-angiotensin-aldosterone system intervention in the cardiometabolic syndrome and cardio-renal protection. Ther Adv Cardiovasc Dis. 2007. 1:27–35.

20. Ferrario CM, Strawn WB. Role of the renin-angiotensin-aldosterone system and proinflammatory mediators in cardiovascular disease. Am J Cardiol. 2006. 98:121–128.

21. Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Circulation prediction of coronary heart disease using risk factor categories. Circulation. 1998. 97:1837–1847.

22. Budoff MJ, Nasir K, Mao S, Tseng PH, Chau A, Liu ST, Flores F, Blumenthal RS. Ethnic differences of the presence and severity of coronary atherosclerosis. Atherosclerosis. 2006. 187:343–350.

23. Kronmal RA, McClelland RL, Detrano R, Shea S, Lima JA, Cushman M, Bild DE, Burke GL. Risk factors for the progression of coronary artery calcification in asymptomatic subjects: results from the Multi-Ethnic Study of Atherosclerosis (MESA). Circulation. 2007. 115:2722–2730.

24. Liu J, Hong Y, D'Agostino RB Sr, Wu Z, Wang W, Sun J, Wilson PW, Kannel WB, Zhao D. Predictive value for the Chinese population of the Framingham CHD risk assessment tool compared with the Chinese Multi-Provincial Cohort Study. JAMA. 2004. 291:2591–2599.

25. D'Agostino RB Sr, Grundy S, Sullivan LM, Wilson P. CHD Risk Prediction Group. Validation of the Framingham coronary heart disease prediction scores: results of a multiple ethnic groups investigation. JAMA. 2001. 286:180–187.

26. Stevens LA, Coresh J, Greene T, Levey AS. Assessing kidney function--measured and estimated glomerular filtration rate. N Engl J Med. 2006. 354:2473–2483.

27. Leung WY, So WY, Tong PC, Chan NN, Chan JC. Effects of structured care by a pharmacist-diabetes specialist team in patients with type 2 diabetic nephropathy. Am J Med. 2005. 118:1414.